IFN-I signature is the most recognized gene signature in SLE, and drugs targeting downstream signaling components such as IFNAR or JAK-STAT are being tested in clinical trials with limited benefit (Richter et al., 2022). The gene discussed is IFNAR1; the disease is systemic lupus erythematosus.